Schrodinger, Inc. Stock Price, News & Analysis

Schrödinger, Inc. (Nasdaq: SDGR) has completed a $6 million all-cash acquisition of XTAL BioStructures, Inc. on January 14, 2022. This strategic acquisition enhances Schrödinger's capabilities in structure-based drug discovery by integrating structural biology services, including biophysical methods and X-ray crystallography. By bringing these services in-house, Schrödinger aims to improve its drug discovery programs through access to high-quality protein structures and bolster its product offerings with validated computational structures.

Schrödinger (Nasdaq: SDGR) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference, with a pre-recorded presentation set for January 10, 2022, at 11:00 a.m. ET. The webcast will be available on-demand on Schrödinger’s website under "News & Events" and archived for seven days. The company is known for its physics-based software platform that accelerates the discovery of therapeutics and materials. Founded in 1990, Schrödinger employs over 500 staff and collaborates globally.

Schrödinger (Nasdaq: SDGR) announces the retirement of CFO Joel Lebowitz, effective February 28, 2022. Lebowitz, who played a key role in the company’s transition to public status and financial growth, will assist in the search for his successor. CEO Ramy Farid commended his contributions, stating that Schrödinger is well-capitalized and positioned for future success. The company reaffirms its full-year 2021 financial guidance, previously announced on November 10, 2021.

Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options to 14 new employees totaling 42,850 shares on December 16, 2021, as part of its 2021 Inducement Equity Incentive Plan. The options have an exercise price of $35.04 per share, reflecting the closing stock price on that date. Each option vests over four years, with 25% vesting after the first year and the remainder monthly over the next three years. Schrödinger leverages its physics-based software platform for drug and material discovery, serving clients in over 70 countries.

Schrödinger, Inc. (SDGR) presented promising preclinical data on its MALT1 inhibitors for treating B-cell lymphomas at the American Society of Hematology Annual Meeting. The data indicate strong anti-tumor activity across various models and highlight the combination potential with existing therapies like ibrutinib. The company aims to submit an Investigational New Drug Application to the FDA in the first half of 2022, potentially expanding treatment options for patients with specific B-cell lymphomas, including ABC-DLBCL and MCL.

Schrödinger (Nasdaq: SDGR) announced its participation in several upcoming investor conferences. Notable events include the 33rd Annual Piper Sandler Virtual Healthcare Conference, the 4th Annual Evercore ISI HealthCONx Conference on November 30, 2021, and the BMO 2021 Growth & ESG Conference on December 7, 2021. Management will also engage in one-on-one meetings during the Berenberg Discover AI Seminar 2021 on December 1. Interested parties can access both live and archived webcasts through the investors section of Schrödinger's website.

Schrödinger (Nasdaq: SDGR) has secured a $4.9 million grant from the Bill & Melinda Gates Foundation to enhance drug discovery for non-hormonal contraceptives. This funding, aimed at a global women's health initiative, focuses on developing safe and effective contraceptive agents with better tolerability versus conventional methods. Schrödinger plans to utilize its advanced drug discovery platform for this project, showcasing its commitment to health and social responsibility objectives.

Schrödinger, Inc. (Nasdaq: SDGR) announced the grant of non-statutory stock options to purchase 7,250 shares of common stock to four newly hired employees on November 15, 2021. This grant, part of the 2021 Inducement Equity Incentive Plan, was made to induce employment acceptance and complies with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $45.45 per share, vesting over four years. Schrödinger utilizes a physics-based software platform for drug and materials discovery, serving various sectors globally.

Schrödinger, Inc. (Nasdaq: SDGR) reported third-quarter 2021 revenue of $29.9 million, up 16% year-over-year. Software revenue was $24.3 million, reflecting growth despite the impact of previous multi-year contracts. Drug discovery revenue increased to $5.6 million, driven by a collaboration with Bristol Myers Squibb. However, gross profit fell to $11.1 million, down from $15.3 million last year. Operating expenses surged to $45.8 million, leading to a net loss of $35 million. The company maintains a full-year revenue outlook of $124 million to $134 million.